Media

German lifestyle magazine Brigitte has profiled our CEO Dr. Daniela Marino in its Macherinnen (female makers) section. Under the title “Meisterin der zweiten Haut” (Master of the second skin), the article retraces her journey from early research at Kinderspital Zürich to the founding of CUTISS and the development of our bio-engineered skin substitute, denovoSkin™. The feature highlights how denovoSkin™ is designed to permanently treat severe burns and large skin defects, sparing donor sites, reducing scarring, and growing with children – bringing new hope to “burn survivors”. You can read the full article as a PDF via the link below. Newsroom Article as PDF

Dutch media have reported on the treatment of the first baby with denovoSkin™, in the Netherlands, outside of clinical trials. The operation was performed by doctors and surgeons at the Burn Centre of the Maasstad Hospital in Rotterdam. Trauma and burn surgeon, Kees van der Vries, described the use of denovoSkin™ a “godsend”. “The baby has been successfully operated on and is recovering well. We are proud to have been able to use this treatment. It really makes a difference for patients with severe, large/extensive burns and contributes to a better quality of life. This innovative method offers promising prospects for the future of burn care.” CUTISS is already running clinical trials, including the ongoing Phase 3 study, in the Netherlands at the Brandwondencentrum Beverwijk. The English language media article is available in the NL Times here, and the original Dutch media article can be read in AD here. The Maasstad Hospital has also published its own article regarding the operation which can be found here. Newsroom Article NL Times

As part of his European tour and trip to Switzerland, BiotechTV host Brad Loncar visited CUTISS to learn more about our work in personalized skin tissue therapy. In this interview, our CEO Dr. Daniela Marino shares insights into the development of denovoSkin™, its clinical progress, and the vision behind advancing skin surgery through bioengineering and automation. Watch the full feature on BiotechTV in the link below. Newsroom Watch feature

Our CEO Daniela Marino has been featured in a new entrepreneurship series launched by Schweizer Monat, the Swiss monthly magazine. In her video interview, she discusses the challenges and rewards of leading CUTISS and our mission to transform skin surgery with denovoSkin™, the bio-engineered skin graft which promises to grow with the patient, minimize scarring and improve quality of life, particularly for children. Daniela also shares candid insights on what it takes to innovate in the biotech space, the importance of resilience, and how balancing her professional and personal life keeps her grounded. You can watch and listen to the interview, in German, here.   Newsroom Video Interview

“The start-up hype of recent years has seen many young entrepreneurs come and go. One who has not only made headlines but also delivered results is Daniela Marino.” Thus reads the opening line of the article published in Switzerland’s business newspaper HandelsZeitung. The article was published on the back of our news in October 2024, announcing the first reconstructive surgery that was done under compassionate use and the first U.S. patient treated with denovoSkin™. Having interviewed Jeremy Goverman M.D. at Massachusetts General Hospital and our CEO Daniela Marino,  the journalist recounts the challenges that we overcame in transporting the personalized skin grafts from Schlieren to Boston, and the wonderful positive outcomes that the surgeons are seeing with the young patient in question. “Daniela and her team are trying to do something that no one else in burn medicine is daring to do. She is developing real skin, not just a substitute,” Jeremy Goverman M.D. is quoted as saying. The link to the article, in German, is available here or on PDF. Newsroom Article (PDF)

Panorama, one of Italy’s leading weekly magazines covering current affairs, culture, and technology, has highlighted Switzerland’s emergence as a global leader in biotechnology, artificial intelligence, and cutting-edge innovation, calling it a “new Silicon Valley”. The article highlights the country’s commitment to advancing science and technology and its ability to foster groundbreaking companies that shape the future of healthcare and beyond. CUTISS is proudly featured as an example of innovation in regenerative medicine and skin tissue engineering. The piece emphasizes our pioneering work in developing the world’s first machine capable of bioengineering personalized human skin grafts, the denovoSkin™, for patients suffering from severe skin injuries. Read the full article in Panorama HERE Newsroom Link to article

The Boston Globe reports on the news that Massachusetts General Hospital has completed the first U.S. application of denovoSkin™, the bi-layer bioengineered skin graft developed by CUTISS, on a young pediatric patient. The reconstructive surgery was performed by Dr. Jeremy Goverman under FDA compassionate use.   Dr. Goverman describes the full-thickness personalized skin graft as a step closer to the “Holy Grail” of reconstructive surgery, potentially transforming skin surgery for both pediatric and adult patients. Read the article here. Newsroom Link to article

The article from Italy’s Quotidiano Nazionale features an interview with our CEO and co-founder Daniela Marino. She discusses our pioneering work in creating bioengineered skin on demand. Daniela highlights the benefits of this technology and our approach which allows us to generate large amounts of skin from a small patient’s own skin sample. More than 60 patients have been treated, among them also an infant. The article also covers CUTISS’s collaborations, including with the Buzzi Pediatric Hospital in Milan, the fundraising efforts, and the significant impact of our innovation on burn victims and reconstructive surgery. For more details, read the full article here. Newsroom Link to article

Tech.eu, the premier online publication dedicated to the growing European technology ecosystem, writes about CUTISS’s breakthrough with denovoSkin, a bioengineered skin graft designed to grow with patients, improving quality of life and significantly reducing the need for follow-up surgeries. The innovative skin graft is derived from a small piece of the patient’s healthy skin and can be produced in large quantities. This advancement offers hope for burn victims and those needing reconstructive surgery. The article also discusses CUTISS’s efforts in automation and our participation in advanced research initiatives, including in space, to enhance our understanding of skin regeneration. For more details, read the full article here. Newsroom Link to article

The Italian daily newspaper La Repubblica writes about our lead product denovoSkin™ being used to treat a child in Milan, Italy.  The young child suffered severe burns over a large portion of his body due to a domestic accident. Traditional skin grafts were not a viable option due to his young age and the extent of the injuries. This patient is now part of the ongoing pediatric clinical trial aimed at demonstrating the efficacy and safety of denovoSkin™ in young kids, who represent a particularly challenging demographic in burn surgery due to their delicate skin and rapid growth rates. A twin study in adolescents and adults has completed recruitment, and safety and efficacy has been recently demonstrated (read the press release here). A third study in reconstructive surgery has completed recruitment (read the press release here). In the article, Professor Gloria Pelizzo, who led the surgical team, noted the successful grafting of our personalized, bioengineered skin graft, highlighting the potential for denovoSkin™ to significantly improve outcomes in pediatric burn treatment. We extend a big thank you to Italian patients, surgeons and investors for being part of CUTISS’ journey. Newsroom Link to article